FDA Approves New, Larger Toujeo Pen

New pen can potentially reduce the number of injections and lower copay costs

The FDA has approved Toujeo (insulin glargine 300 units/mL, Sanofi) Max SoloStar, the highest capacity long-acting insulin pen that will be available on the market. The new pen holds 900 units of Toujeo, more than any other long-acting insulin pen in the U.S., and provides up to 160 units/mL of Toujeo in a single injection.

Due to its higher capacity, Max SoloStar may reduce the number of pens adults prescribed Toujeo use, allowing for fewer refills and related copays, depending on the person’s insurance coverage. The maximum dose of up to 160 units/mL may also help reduce the number of injections needed to deliver the required Toujeo dosage for some adults with diabetes.

Toujeo Max SoloStar will be available at the same price as the original Toujeo SoloStar per insulin unit. The new pen will launch in retail pharmacies across the U.S. in the third quarter of 2018.

Source: Sanofi; March 27, 2018.

Career Opportunities

HAP, a subsidiary of Henry Ford Health System, is a nonprofit health plan providing coverage to individuals, companies and organizations. This executive develops strategies to meet membership and revenue targets through products, pricing, market segmentation and advertising.  Aligns business among Business Development, Commercial Sales, Medicare and Public Sector Programs and Product Development. Seeks to enhance and be responsible for business development and expansion through the development of an effective product portfolio, strong interpersonal relationships and service excellence.

Apply via email to jfedder1@hfhs.org or online at http://p.rfer.us/HENRYFORDlXqAJA